Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 19/20 | 0.56 |
| ▸ | MMP13 | P45452 | 19/20 | 0.56 |
| ▸ | MMP2 | P08253 | 9/20 | 0.56 |
| ▸ | MMP9 | P14780 | 9/20 | 0.56 |
| ▸ | MMP3 | P08254 | 8/20 | 0.56 |
| ▸ | MMP7 | P09237 | 6/20 | 0.56 |
| ▸ | MMP8 | P22894 | 5/20 | 0.56 |
| ▸ | ADAM17 | P78536 | 14/20 | 0.54 |
| ▸ | MMP14 | P50281 | 2/20 | 0.53 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.48 |
| ▸ | ADAM9 | Q13443 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6109667 | 1.00 | MMP1 (0.56) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6759512 | 0.87 | MMP1 (0.65) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6498714 | 0.87 | MMP1 (0.65) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6108782 | 0.87 | MMP1 (0.58) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6429978 | 0.85 | MMP1 (0.63) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6429984 | 0.85 | MMP1 (0.63) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6500840 | 0.84 | MMP1 (0.58) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6501049 | 0.84 | MMP1 (0.58) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6429129 | 0.84 | MMP1 (0.74) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6429127 | 0.84 | MMP1 (0.74) | MMP1MMP13MMP2MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7282496-B2 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and TACE inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| EP-1440057-A1 | ALLENIC ARYL SULFONAMIDE HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | Wyeth Holdings Corporation (US) | 2004-07-28 | — | — | EP | disclosed |
| US-20030130238-A1 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2003-07-10 | — | — | US | disclosed |
| WO-2003037852-A1 | ALLENIC ARYL SULFONAMIDE HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | WYETH HOLDINGS CORPORATION (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130238-A1 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors | MMP12, MMP1, SI | MMP1 2/4885MMP13 11/4885MMP2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.